Amebiasis and Infection with Free-Living Amebae

Chapter 230 | Part 5: Infectious Diseases

KEY CLINICAL POINTS

• Amebiasis is caused by Entamoeba histolytica, with 90% of cases being asymptomatic colonization and 10% progressing to invasive disease.
• Metronidazole and tinidazole are first-line treatments for invasive amebiasis, with tinidazole offering single-dose therapy due to its long half-life.
• Amebic liver abscess is the most common extraintestinal manifestation, with metronidazole as the drug of choice, and surgical drainage required for complications like rupture.
• Free-living amebae (Naegleria, Acanthamoeba, Balamuthia) cause severe CNS infections, with Naegleria fowleri causing rapid, fatal meningoencephalitis.
• Prevention focuses on sanitation, avoiding contaminated water, and proper contact lens care to reduce keratitis risk from Acanthamoeba.

1. DEFINITION & OVERVIEW

Amebiasis is an infection caused by Entamoeba histolytica, an intestinal protozoan. Clinical syndromes range from asymptomatic colonization (90% of cases) to invasive disease (10% of cases), including intestinal colitis or extraintestinal abscesses (e.g., liver).

Table 230-1 Drug Therapy for Amebiasis

INDICATION	THERAPY
Asymptomatic carriage	Luminal agent: iodoquinol (650 mg tid for 20 days) or paromomycin (500 mg tid for 10 days)
Acute colitis	Metronidazole (750 mg PO/IV tid for 5–10 days) or tinidazole (2 g PO once) plus luminal agent
Amebic liver abscess	Metronidazole (750 mg PO/IV for 5–10 days) or tinidazole (2 g PO once) plus luminal agent

1.1 Life Cycle and Transmission

E. histolytica is acquired via ingestion of viable cysts from fecally contaminated water, food, or hands. Cysts excyst in the small intestine, releasing trophozoites that may invade the bowel or bloodstream, causing abscesses. Transmission via sexual practices or contaminated soil is less common.

1.2 Differentiation from Other Species

E. histolytica differs from E. dispar (non-pathogenic) and E. moshkovskii (associated with mixed infections) by unique surface antigens and virulence factors. Serologic tests and microscopic identification of ingested erythrocytes are critical for diagnosis.

2. EPIDEMIOLOGY

E. histolytica infection is endemic in tropical regions with poor sanitation, affecting children <5 years old. In developed countries, risk factors include travel, immigration, and sexual practices. Global mortality is 26,748/year, with 10% of cases in children <5.

2.1 Demographics

Men are 10–12 times more likely than women to develop invasive disease, attributed to testosterone's effect on immune response. Amebic liver abscesses are most common in men aged 30–60.

2.2 Free-Living Amebae

Naegleria fowleri (warm freshwater), Acanthamoeba (tap water, contact lenses), and Balamuthia (soil) cause CNS infections. Outbreaks linked to contaminated water and organ transplantation.

3. ETIOLOGY & PATHOPHYSIOLOGY

E. histolytica virulence factors include proteases degrading mucus, cysteine proteases causing tissue damage, and resistance to oxidative stress. Immune evasion via thioredoxin system and interaction with gut microbiome (e.g., Prevotella copri) modulate disease severity.

3.1 Pathogenesis

Trophozoites invade colonic mucosa, causing ulcers and abscesses. In liver, abscesses form via hematogenous spread. Cyst formation and encystation allow survival in the environment.

3.2 Immune Response

IgA and IgG responses are critical; maternal IgA confers passive immunity. Neutrophilic infiltration and cytokine production (e.g., TNF- α , IL-6) mediate inflammation.

4. CLINICAL FEATURES

Intestinal amebiasis presents with dysentery, abdominal pain, or asymptomatic cyst passage. Amebic liver abscesses cause fever, right upper quadrant pain, and systemic symptoms. Complications include rupture into pleura/pericardium or peritoneum.

4.1 Intestinal Manifestations

Acute colitis: dysentery with blood/mucus stools, fever. Chronic: ulcers, malabsorption, and ameboma (bowel mass).

4.2 Extraintestinal Manifestations

Liver abscesses (most common), pulmonary, cerebral, or cutaneous involvement. Cerebral amebiasis is rare (<0.1%) but often fatal.

5. DIFFERENTIAL DIAGNOSIS

Bacterial diarrheas (Campylobacter, Shigella, Salmonella), other protozoa (Giardia, Cryptosporidium), and inflammatory bowel disease. Amebic liver abscess must be differentiated from pyogenic abscesses.

6. INVESTIGATIONS & DIAGNOSIS

Stool exams (heme, trophozoites), serology (ELISA, PCR), imaging (ultrasound, CT for liver abscesses). PCR and LAMP assays improve detection of E. histolytica DNA.

6.1 Diagnostic Tests

Stool microscopy for trophozoites/cysts; serology for IgG/IgA; PCR for rapid detection. Amebic liver abscess confirmed by imaging and aspiration.

6.2 Imaging

CT/MRI for liver abscesses (right lobe, >10 cm). Ultrasound for follow-up. MRI for CNS infections (Balamuthia, Naegleria).

7. MANAGEMENT & TREATMENT

Luminal agents (iodoquinol, paromomycin) for asymptomatic carriers. Metronidazole/tinidazole for invasive disease. Surgical drainage for abscess rupture. Supportive care for complications.

7.1 Drug Therapy

Metronidazole (5–10 days) for colitis/abscess; tinidazole (single dose) for liver abscess. Luminal agents to eradicate cysts. Combination therapy for severe cases.

7.2 Free-Living Amebae

Naegleria: miltefosine + amphotericin B. Acanthamoeba: keratoplasty + antifungals. Balamuthia: miltefosine + pentamidine. Early diagnosis critical for survival.

8. PROGNOSIS & COMPLICATIONS

Invasive amebiasis has 1–5% mortality. Liver abscesses with rupture have poor outcomes. Complications include peritonitis, meningitis, and sepsis. Amebic keratitis may lead to blindness.

8.1 Prognostic Factors

Early diagnosis, immune status, and treatment adherence. Amebic liver abscesses respond well to metronidazole, but complications like rupture worsen prognosis.

9. SPECIAL CONSIDERATIONS

Pregnancy: avoid metronidazole. Pediatrics: focus on stool exams and luminal agents. Immunocompromised patients (e.g., HIV, transplant recipients) at higher risk for invasive disease. Avoid contact lens use in contaminated water.

10. KEY POINTS & CLINICAL PEARLS

1. Distinguish E. histolytica from E. dispar using serology and trophozoite morphology. 2. Metronidazole is first-line for invasive disease, with tinidazole as single-dose alternative. 3. Amebic liver abscess requires imaging and drainage for complications. 4. Free-living amebae cause fatal CNS infections; prevention focuses on water safety. 5. Acanthamoeba keratitis requires prompt keratoplasty and antifungal therapy.